Biovail Corp. has received approval from the United States Food and Drug Administration to sell its a formulation of the antidepressant citalopram. The company said Wednesday it received an approval letter from the FDA for an orally disintegrating tablet formulation of citalopram hydrobromide.
“Biovail believes that its novel formulation of citalopram HBr may offer physicians a new dosing option with potential benefits and prescribing flexibility that may be advantageous when addressing the needs of certain patients,” the company said in a release.
The formulation, designed for patients who have trouble swallowing tablets or do not have access to water, will be available in 10mg, 20mg and 40mg tablets by prescription.
Toronto-based Biovail (TSX:BVF) develops and manufactures drugs for the treatment of a variety of medical conditions.